These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11353603)

  • 1. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
    Hammond JL; Koontz DL; Bazmi HZ; Beadle JR; Hostetler SE; Kini GD; Aldern KA; Richman DD; Hostetler KY; Mellors JW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1621-8. PubMed ID: 11353603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
    Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
    J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
    Tachedjian G; Mellors J; Bazmi H; Birch C; Mills J
    J Virol; 1996 Oct; 70(10):7171-81. PubMed ID: 8794364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.
    Meyer PR; Matsuura SE; Zonarich D; Chopra RR; Pendarvis E; Bazmi HZ; Mellors JW; Scott WA
    J Virol; 2003 Jun; 77(11):6127-37. PubMed ID: 12743270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
    Schott H; Hamprecht K; Schott S; Schott TC; Schwendener RA
    Bioorg Med Chem; 2009 Jan; 17(1):303-10. PubMed ID: 19010684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
    Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
    Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine.
    Hostetler KY; Hammond JL; Kini GD; Hostetler SE; Beadle JR; Aldern KA; Chou TC; Richman DD; Mellors JW
    Antivir Chem Chemother; 2000 May; 11(3):213-9. PubMed ID: 10901292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
    Arion D; Sluis-Cremer N; Parniak MA
    J Biol Chem; 2000 Mar; 275(13):9251-5. PubMed ID: 10734063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiviral evaluation of SATE-foscarnet prodrugs and new foscarnet-AZT conjugates.
    Meier C; Aubertin AM; de Monte M; Faraj A; Sommadossi JP; Périgaud C; Imbach JL; Gosselin G
    Antivir Chem Chemother; 1998 Jan; 9(1):41-52. PubMed ID: 9875376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity.
    Lazaro JB; Boretto J; Selmi B; Capony JP; Canard B
    Biochem Biophys Res Commun; 2000 Aug; 275(1):26-32. PubMed ID: 10944435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate.
    Tramontano E; Piras G; Mellors JW; Putzolu M; Bazmi HZ; La Colla P
    Biochem Pharmacol; 1998 Dec; 56(12):1583-9. PubMed ID: 9973178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY; Vrang L; Oberg B; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro.
    Hostetler KY; Kini GD; Beadle JR; Aldern KA; Gardner MF; Border R; Kumar R; Barshak L; Sridhar CN; Wheeler CJ; Richman DD
    Antiviral Res; 1996 Jun; 31(1-2):59-67. PubMed ID: 8793009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.